These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 17224002

  • 1. Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis.
    Then Bergh F, Kümpfel T, Yassouridis A, Lechner C, Holsboer F, Trenkwalder C.
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):295-303. PubMed ID: 17224002
    [Abstract] [Full Text] [Related]

  • 2. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T, Schwan M, Pollmächer T, Yassouridis A, Uhr M, Trenkwalder C, Weber F.
    Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
    [Abstract] [Full Text] [Related]

  • 3. Adenohypophyseal function in bitches treated with medroxyprogesterone acetate.
    Beijerink NJ, Bhatti SF, Okkens AC, Dieleman SJ, Mol JA, Duchateau L, Van Ham LM, Kooistra HS.
    Domest Anim Endocrinol; 2007 Feb; 32(2):63-78. PubMed ID: 16455223
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of interferon-beta 1a on the hypothalamic-pituitary-adrenal axis, leukocyte distribution and mood states in multiple sclerosis patients: results of a 1-year follow-up study.
    Goebel MU, Czolbe F, Becker H, Janssen OE, Schedlowski M, Limmroth V.
    Eur Neurol; 2005 Feb; 53(4):182-7. PubMed ID: 15947464
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 8. Low serum dehydroepiandrosterone sulfate in women with primary Sjögren's syndrome as an isolated sign of impaired HPA axis function.
    Valtysdóttir ST, Wide L, Hällgren R.
    J Rheumatol; 2001 Jun; 28(6):1259-65. PubMed ID: 11409117
    [Abstract] [Full Text] [Related]

  • 9. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
    Owashi T, Otsubo T, Oshima A, Nakagome K, Higuchi T, Kamijima K.
    Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
    [Abstract] [Full Text] [Related]

  • 10. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L, Paolino E, Tola MR, Granieri E, Baricordi OR.
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [Abstract] [Full Text] [Related]

  • 11. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
    Ysrraelit MC, Gaitán MI, Lopez AS, Correale J.
    Neurology; 2008 Dec 09; 71(24):1948-54. PubMed ID: 19064876
    [Abstract] [Full Text] [Related]

  • 12. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis.
    Gottschalk M, Kümpfel T, Flachenecker P, Uhr M, Trenkwalder C, Holsboer F, Weber F.
    Arch Neurol; 2005 Feb 09; 62(2):277-80. PubMed ID: 15710856
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
    Clin Neuropharmacol; 2008 Feb 09; 31(3):167-72. PubMed ID: 18520983
    [Abstract] [Full Text] [Related]

  • 14. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 09; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 15. Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis.
    Jorgensen C, Bressot N, Bologna C, Sany J.
    J Rheumatol; 1995 Oct 09; 22(10):1829-33. PubMed ID: 8991978
    [Abstract] [Full Text] [Related]

  • 16. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus.
    Köller MD, Templ E, Riedl M, Clodi M, Wagner O, Smolen JS, Luger A.
    Ann Rheum Dis; 2004 Dec 09; 63(12):1677-80. PubMed ID: 15082470
    [Abstract] [Full Text] [Related]

  • 17. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
    Hernandez-Perez MA, Grupo de Investigadores Del Estudio PARALEN.
    Rev Neurol; 2004 Dec 09; 48(10):505-8. PubMed ID: 19434583
    [Abstract] [Full Text] [Related]

  • 18. Suppression and recovery of the hypothalamic function after high-dose corticosteroid treatment in preterm infants.
    Ng PC, Lam CW, Lee CH, Chan IH, Wong SP, Fok TF.
    Neonatology; 2008 Dec 09; 94(3):170-5. PubMed ID: 18612214
    [Abstract] [Full Text] [Related]

  • 19. Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis.
    Lizcano F, Salvador J.
    Clin Exp Pharmacol Physiol; 2008 Sep 09; 35(9):1085-90. PubMed ID: 18505442
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis.
    Safarinejad MR.
    J Neuroendocrinol; 2008 Dec 09; 20(12):1368-75. PubMed ID: 19094084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.